Molecule News and Research

RSS

Avila's PI3Kα inhibitor preclinical study data presented at AACR meeting

Avila Therapeutics, Inc., a biotechnology company developing novel targeted covalent drugs, today presented results of preclinical studies on its novel Phosphoinositide 3-kinase alpha inhibitor at the American Association for Cancer Research 102nd Annual Meeting in Orlando, Florida.

6 Apr 2011

CIC microGUNE uses DNA stretching technique to detect illnesses

Making DNA sequences being passed through nanochannels a thousand times thinner than a human hair to the point that they take on the form of diminutive spaghetti.

6 Apr 2011

OSU chemist developing solution to nerve agent exposure

Scientists are working to develop a new drug that will regenerate a critical enzyme in the human body that “ages” after a person is exposed to deadly chemical warfare agents.

5 Apr 2011

La Jolla acquires GliaMed's novel class of compounds

La Jolla Pharmaceutical Company today announced that it has acquired the rights to a novel class of compounds known as Regenerative Immunophilin Ligands from privately held GliaMed, Inc.

5 Apr 2011

Synta presents ganetespib and elesclomol study data in cancer at AACR meeting

Synta Pharmaceuticals Corp. today presented five posters at the American Association for Cancer Research 102nd Annual Meeting. Three posters reported results from studies of ganetespib, and two posters reported results from studies of elesclomol, a small-molecule mitochondria metabolism inhibitor.

5 Apr 2011

Curis presents vismodegib Phase II data in basal cell nevus syndrome at AACR meeting

Curis, Inc., a drug development company seeking to develop next generation targeted small molecule drug candidates for cancer treatment, today announced the presentation of interim Phase II clinical data on Hedgehog pathway inhibitor vismodegib in patients with basal cell nevus syndrome, which is also commonly referred to as Gorlin syndrome.

5 Apr 2011

Lilly presents results of JAK2, Hedgehog inhibitor preclinical cancer studies at 102nd AACR

Eli Lilly and Company announced results today from two preclinical studies of molecules that target genetic mutations and disable specific signaling pathways that can lead to cancer. The studies evaluated two unique molecules – a JAK2 inhibitor and a Hedgehog inhibitor – with results presented during the American Association for Cancer Research (AACR) 102nd Annual Meeting in Orlando, Fla.

5 Apr 2011

Oncothyreon's ONT-10, PX-866 preclinical data presented at AACR meeting

Oncothyreon Inc. today announced the presentation of preclinical data for ONT-10, a therapeutic vaccine directed at cancers expressing MUC1, and PX-866, its irreversible inhibitor of phosphatidylinositol 3-kinase, at the American Association of Cancer Research meeting in Orlando, Florida.

4 Apr 2011

Research offers first structural insights into 'client' protein shape in chaperone presence

In the constantly morphing field of protein structure, scientists at The Scripps Research Institute offer yet another surprise: a common "chaperone" protein in cells thought to help other proteins fold has been shown instead to loosen them.

4 Apr 2011

Life Technologies launches new TaqMan Mutation Detection Assays

Life Technologies Corporation today announced the launch of its TaqMan Mutation Detection Assays -- highly sensitive and novel molecular analysis research tools with the precision to detect a single mutant molecule hiding in a background of 1 million normal copies.

4 Apr 2011

New research: 'Good cholesterol' can act as special delivery vehicle for cancer destruction

High-density lipoprotein's hauls excess cholesterol to the liver for disposal, but new research suggests "good cholesterol" can also act as a special delivery vehicle of destruction for cancer.

1 Apr 2011

Neogenix Oncology to present laboratory studies of NEO-101 at AACR Annual Meeting

Neogenix Oncology, Inc. announced today that members of its scientific staff will present laboratory studies of NEO-101, a novel monoclonal antibody in development to diagnose and treat pancreatic and colorectal cancers.

1 Apr 2011

Glenmark initiates IND enabling studies of GBR 401 anti-CD19 monoclonal antibody in B cell lymphomas

Glenmark Pharmaceuticals announces the discovery and initiation of IND enabling studies of a Novel Biological Entity (NBE) lead candidate, GBR 401, an anti-CD19 monoclonal antibody. GBR 401 is developed completely in-house by Glenmark's Biologics Research Centre located in Switzerland.

1 Apr 2011

New discovery on IL-23 can lead to novel IBD treatments

A new discovery published in the April 2001 issue of Journal of Leukocyte Biology raises hope that new treatments for illnesses like Crohn's disease and ulcerative colitis are on the horizon.

1 Apr 2011

Micro-RNAs appear to play a key role in new mechanism underlying obesity

Max Planck researchers have discovered a new mechanism that leads to the development of type 2 diabetes in obesity. Body weight influences the risk of developing diabetes: between 80 and 90 percent of patients with type 2 diabetes are overweight or obese.

31 Mar 2011

Towards accurate simulation of whole working cells

Researchers have built a computer model of the crowded interior of a bacterial cell that - in a test of its response to sugar in its environment - accurately simulates the behavior of living cells.

31 Mar 2011

Basic Yellow 1 dye extends lifespan in healthy nematodes, slows Alzheimer's disease-like pathology in worms

Basic Yellow 1, a dye used in neuroscience laboratories around the world to detect damaged protein in Alzheimer's disease, is a wonder drug for nematode worms. In a study appearing in the March 30, online edition of Nature, the dye, also known as Thioflavin T, (ThT) extended lifespan in healthy nematode worms by more than 50 percent and slowed the disease process in worms bred to mimic aspects of Alzheimer's.

31 Mar 2011

Accelrys announces Modeling and Simulation Suite for optimizing R&D value chain

Accelrys, Inc., a leading scientific enterprise R&D software and services company, today announced the Accelrys Modeling and Simulation Suite, a pillar of the new Accelrys Enterprise R&D Architecture.

30 Mar 2011

Multiple drugs bonded to 'transport vehicle' bypass healthy cells to attack breast cancer from inside

Researchers at Cedars-Sinai's Maxine Dunitz Neurosurgical Institute have employed a strategy using a mouse model to target important mechanisms inside the most challenging breast cancer cells. Earlier studies at Cedars-Sinai found a similar approach effective in attacking malignant brain tumor targets.

30 Mar 2011

Researchers develop new drug for multiple cancer treatment

Researchers at the University of Michigan Comprehensive Cancer Center have developed a new drug called AT-406 with potential to treat multiple types of cancer.

30 Mar 2011

Molecule News and Research

Avila's PI3Kα inhibitor preclinical study data presented at AACR meeting

CIC microGUNE uses DNA stretching technique to detect illnesses

OSU chemist developing solution to nerve agent exposure

La Jolla acquires GliaMed's novel class of compounds

Synta presents ganetespib and elesclomol study data in cancer at AACR meeting

Curis presents vismodegib Phase II data in basal cell nevus syndrome at AACR meeting

Lilly presents results of JAK2, Hedgehog inhibitor preclinical cancer studies at 102nd AACR

Oncothyreon's ONT-10, PX-866 preclinical data presented at AACR meeting

Research offers first structural insights into 'client' protein shape in chaperone presence

Life Technologies launches new TaqMan Mutation Detection Assays

New research: 'Good cholesterol' can act as special delivery vehicle for cancer destruction

Neogenix Oncology to present laboratory studies of NEO-101 at AACR Annual Meeting

Glenmark initiates IND enabling studies of GBR 401 anti-CD19 monoclonal antibody in B cell lymphomas

New discovery on IL-23 can lead to novel IBD treatments

Micro-RNAs appear to play a key role in new mechanism underlying obesity

Towards accurate simulation of whole working cells

Basic Yellow 1 dye extends lifespan in healthy nematodes, slows Alzheimer's disease-like pathology in worms

Accelrys announces Modeling and Simulation Suite for optimizing R&D value chain

Multiple drugs bonded to 'transport vehicle' bypass healthy cells to attack breast cancer from inside

Researchers develop new drug for multiple cancer treatment

Why use light scattering to analyze proteins and viral vectors?

Changing the landscape of R&D to build clinical success from the ground up

Sensing a Healthier Future

Latest News